Wednesday, May 29, 2013

Body Blow To Biotechnology?

Ahead of the keenly-anticipated United States Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics,  The Financial Times ran an article on May 28, 2013, entitled "Supreme Court:  US genes patent decision may depend on strands in Myriad argument."  The article includes the following passage:
Before [the Myriad case] was heard [by the United States Supreme Court], one patent expert predicted the results could be disastrous. 
"Synthetic DNA sequences, designed by humans, may be excluded from this prohibition but the invalidation of patents claiming human genes will wipe out vast amounts of private investment, and be a body blow to the biotechnology industry," says Andrew Torrance, professor at the University of Kansas law school.
The decision in Myriad should arrive within days.  The biotechnology industry awaits it with bated breath.